Literature DB >> 2959206

[Conversion of 5'-deoxy-5-fluorouridine to 5-FU by pyrimidine nucleoside phosphorylases in normal and tumor tissues from rodents bearing tumors and cancer patients].

M Miwa1, J Nishimura, T Kamiyama, H Ishitsuka.   

Abstract

Enzyme levels of pyrimidine nucleoside phosphorylase, which is an essential enzyme for the phosphorolysis of 5'-deoxy-5-fluorouridine (5'-DFUR) to 5-fluorouracil (5-FU), in normal and tumor tissues were investigated. In all mouse strains tested, the enzyme level was found to be higher in the small intestine and stomach than other tissues, while in rats a higher level of the enzyme in the lung was also observed additionally. The enzyme levels of tumor tissues varied in tumor cell lines transplanted. P388 leukemia, Ehrlich ascites carcinoma, sarcoma 180, colon 26 carcinoma, and Lewis lung carcinoma cells contained high levels of the enzyme and the mice bearing these tumors responded well to the therapy with 5'-DFUR than its active metabolite 5-FU, while 5'-DFUR did not show clear advantage over 5-FU against L1210 or LSTRA leukemia, in which the enzyme levels were low. These results indicate that there is some correlation between the enzyme level and antitumor efficacy of 5'-DFUR. In human specimens, the enzyme levels were 2-6 times higher in tumors than those of the corresponding normal tissues and those adjacent to the tumors. These results predict that 5'-DFUR seemed to be converted efficiently to 5-FU also in human tumors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2959206

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  6 in total

1.  Inhibitory effects of fluorinated pyrimidines, 5'-DFUR, UFT and T-506, in a model of hepatic metastasis of mouse colon 26 adenocarcinoma-assessment of inhibitory activity and adverse reactions at the maximum tolerated dose.

Authors:  K Tazawa; T Sakamoto; Y Kuroki; I Yamashita; M Okamoto; S Katuyama; M Fujimaki
Journal:  Clin Exp Metastasis       Date:  1997-05       Impact factor: 5.150

2.  Enhancement of drug sensitivity and a bystander effect in PC-9 cells transfected with a platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA.

Authors:  Y Kato; S Matsukawa; R Muraoka; N Tanigawa
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Effect of coadministered uridine on intestinal first-pass metabolism of 5'-deoxy-5-fluorouridine in conscious rats--an evaluation by method of portal-systemic concentration difference.

Authors:  Y Sawai; K Yamaoka; T Nakagawa
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

4.  Expression of thymidine phosphorylase in primary human renal cell carcinoma by ELISA method.

Authors:  Hidetoshi Kinsui; Takeshi Ueda; Hiroyoshi Suzuki; Shigeo Isaka; Nobuyuki Sekita; Akira Komiya; Toyofusa Tobe; Tomonori Yamanishi; Koichiro Akakura; Tomohiko Ichikawa; Tatsuo Igarashi; Haruo Ito
Journal:  Jpn J Cancer Res       Date:  2002-03

5.  Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma.

Authors:  K Maeda; Y S Chung; Y Ogawa; S Takatsuka; S M Kang; M Ogawa; T Sawada; N Onoda; Y Kato; M Sowa
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

6.  Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma.

Authors:  T Ishikawa; Y Tanaka; H Ishitsuka; T Ohkawa
Journal:  Jpn J Cancer Res       Date:  1989-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.